Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7751783 | 0.86 | CNR1 (0.51) | CNR1CNR2FAAHCTSDTDP1 | |
| SCHEMBL7397008 | 0.82 | EPHX1 (0.49) | CNR1CNR2HPGDCTSDKMT2A | |
| SCHEMBL20324937 | 0.80 | HPGD (0.34) | FAAHHPGDCTSDKMT2AMEN1 | |
| SCHEMBL20857323 | 0.78 | HPGD (0.56) | FAAHHPGDKMT2AMEN1MAPK1 | |
| SCHEMBL4341580 | 0.76 | HPGD (0.59) | HPGDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL8909364 | 0.76 | MEN1 (0.54) | FAAHHPGDKMT2AMEN1MAPK1 | |
| SCHEMBL21341571 | 0.75 | SMN1; SMN2 (0.55) | HPGDKMT2AMEN1MAPK14SMN1; SMN2 | |
| SCHEMBL27259447 | 0.74 | HTR4 (0.43) | CNR1CNR2FAAHHPGDALDH1A1 | |
| SCHEMBL29316643 | 0.72 | HPGD (0.39) | GLAFAAHHPGDKMT2AMEN1 | |
| SCHEMBL26741623 | 0.72 | HPGD (0.39) | GLAFAAHHPGDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | CNR1 4495/4885CNR2 4479/4885GLA 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.